Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  British American Tobacco    BATS   GB0002875804

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

British American Tobacco : Switching from smoking to glo significantly reduces exposure to toxicants

share with twitter share with LinkedIn share with facebook
share via e-mail
03/08/2018 | 06:13pm CET

By a News Reporter-Staff News Editor at Clinical Trials Week -- A clinical study conducted by scientists at British American Tobacco have revealed that when smokers switch completely from cigarettes to glo, their exposure to certain cigarette smoke toxicants is significantly reduced, in some cases to levels comparable to those seen in smokers who quit smoking completely (see also R&D at British American Tobacco).

These results add to evidence suggesting that glo may have the potential to be substantially reduced risk compared to smoking conventional cigarettes.

glo is a tobacco heating product (THP) designed to heat rather than burn tobacco. This means it does not produce smoke and certain toxicants associated with tobacco combustion are substantially reduced. Previous studies revealed toxicant levels in the heated tobacco vapour from glo to be around 90-95% less than in cigarette smoke.

'Products like glo are very new and consumers and regulators alike understandably want as much information as possible about them. Understanding how vapour from glo compares to cigarette smoke is, therefore, a core component of our scientific research,' said Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco. 'Clinical studies, which are studies involving real people, are an extremely important component of that,' he said.

Because glo vapour has lower levels of toxicants than cigarette smoke, it should in principle expose consumers to much less toxicants. The results of this study indicate that this is indeed the case. The results are presented today at the annual conference of the Society for Nicotine and Tobacco Research in Baltimore, Maryland, USA.

This clinical study was conducted in Japan because THPs like glo are popular there. One hundred and eighty people participated in the study, which was conducted over a period of eight days in a clinic. They were all smokers for at least three years prior to enrolment.

For the first two days, study participants continued to smoke as normal and their urine was collected to measure levels of chemicals. Blood and breath were also collected for analysis.

For the next five days, participants were randomly allocated to either continue smoking, switch to using a THP or quit smoking. Urine, blood and breath samples were again collected for analysis.

Exposure to certain smoke toxicants was determined by measuring the levels of certain chemicals in the urine. These could be the toxicants themselves or their metabolites - which is what the body breaks it down into - called biomarkers of exposure. Toxicants measured included those identified by the World Health Organisation as being of concern in cigarette smoke.

The results show that the concentration of certain chemicals in the urine was reduced in smokers who switched to glo. In some cases, these reductions were the same as those in smokers who quit (Figure 1). This suggests that smokers who switched to glo were exposed to less toxicants - in some cases, their exposure was the same as smokers who quit altogether.

'These results are very encouraging,' explains Murphy. 'The next step will be to determine whether this reduction in exposure translates to a reduced biological effect, and in turn a reduction in adverse health effects for those smokers who switch completely to glo,' he said.

Future clinical studies will test for markers of biological effect, like cholesterol levels or heart rate (i.e. measurements that give an indication of general health). A reduction in biomarkers of biological effect could suggest that a reduction in exposure is having a positive impact on reducing the adverse health risks of smokers who switch completely.

'The results of one test are important,' said Murphy, 'but it is the combination of the results of many different tests that start to give us a real feel for the bigger picture and the potential for glo to be reduced risk compared to a conventional cigarette.'

Keywords for this news article include: Smoking, Chemicals, Clinical Research, Health and Medicine, Risk and Prevention, Clinical Trials and Studies, R&D at British American Tobacco.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
09:55aBRITISH AMERICAN TOBACCO : directors get 5% pay increase
06:04aBRITISH AMERICAN TOBACCO : directors get 5% pay increase
03/22BRITISH AMERICAN TOBACCO : Ex-dividend day for for quarterly dividend
03/19OPINION : British American Tobacco is the darling of fund managers
03/19OPINION : British American Tobacco is the darling of fund managers
03/16Japan Tobacco to buy Russian tobacco group Donskoy in $1.6 billion deal
03/15BRITISH AMERICAN TOBACCO : British American Tobacco underlines commitment to tra..
03/15FDA Moves to Curb Nicotine in Cigarettes
03/09PHILIP MORRIS INTERNATIONAL : How children around the world are exposed to cigar..
03/08BRITISH AMERICAN TOBACCO : Researchers Submit Patent Application, "Apparatus for..
More news
News from SeekingAlpha
03/21British American Tobacco goes ex-dividend tomorrow 
03/20FDA moves toward menthol tobacco rule; British American most vulnerable 
03/18ETF MONTH #4 : Developed Markets (Ex-North America) With EFA. But Is There A Bet.. 
03/16Long road seen for new FDA nicotine rule 
Financials ( GBP)
Sales 2018 24 882 M
EBIT 2018 10 576 M
Net income 2018 6 756 M
Debt 2018 43 048 M
Yield 2018 5,22%
P/E ratio 2018 12,70
P/E ratio 2019 11,64
EV / Sales 2018 5,30x
EV / Sales 2019 5,00x
Capitalization 88 867 M
Duration : Period :
British American Tobacco Technical Analysis Chart | BATS | GB0002875804 | 4-Traders
Technical analysis trends BRITISH AMERICAN TOBACCO
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 53,8  GBP
Spread / Average Target 39%
EPS Revisions
Nicandro Durante Chief Executive Officer & Executive Director
Richard George William Burrows Chairman
Alan Davy Director-Group Operations
John Benedict Stevens Executive Director & Finance Director
David O'Reilly Group Scientific Director & Director-Research
Sector and Competitors
1st jan.Capitalization (M$)
IMPERIAL BRANDS-26.45%31 420
SWEDISH MATCH11.91%8 030
ESSENTRA-14.71%1 693
PHILIP MORRIS CR, A.S.--.--%1 647